loading
전일 마감가:
$124.38
열려 있는:
$123.45
하루 거래량:
7,450
Relative Volume:
0.01
시가총액:
$7.43B
수익:
$343.51M
순이익/손실:
$-530.29M
주가수익비율:
-10.97
EPS:
-11.3176
순현금흐름:
$-610.17M
1주 성능:
-1.14%
1개월 성능:
-4.50%
6개월 성능:
+0.01%
1년 성능:
+31.55%
1일 변동 폭
Value
$122.42
$124.09
1주일 범위
Value
$118.05
$133.00
52주 변동 폭
Value
$90.13
$161.00

Ascendis Pharma A S Adr Stock (ASND) Company Profile

Name
명칭
Ascendis Pharma A S Adr
Name
전화
-
Name
주소
-
Name
직원
879
Name
트위터
Name
다음 수익 날짜
2024-12-13
Name
최신 SEC 제출 서류
Name
ASND's Discussions on Twitter

ASND을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
ASND 123.47 7.43B 343.51M -530.29M -610.17M -11.32
VRTX 447.95 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.90 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 589.67 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.92 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.56 24.49B 3.30B -501.07M 1.03B 11.54

Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-12-20 개시 Jefferies Buy
2023-06-14 재개 Credit Suisse Neutral
2023-04-05 다운그레이드 Oppenheimer Outperform → Perform
2023-04-04 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2023-04-03 다운그레이드 Credit Suisse Outperform → Neutral
2022-10-20 개시 Goldman Buy
2022-08-30 재개 Berenberg Buy
2022-03-28 재개 Wedbush Outperform
2022-03-15 업그레이드 BofA Securities Neutral → Buy
2022-03-01 개시 Citigroup Buy
2022-02-14 업그레이드 Oppenheimer Perform → Outperform
2022-01-06 개시 Cowen Market Perform
2021-12-08 개시 Wells Fargo Overweight
2021-10-20 다운그레이드 BofA Securities Buy → Neutral
2021-03-30 다운그레이드 Oppenheimer Outperform → Perform
2021-03-11 재개 Stifel Buy
2020-12-17 개시 Berenberg Buy
2020-09-14 재개 JP Morgan Overweight
2020-03-20 개시 Oppenheimer Outperform
2019-10-11 개시 Morgan Stanley Overweight
2019-03-25 개시 Evercore ISI Outperform
2019-01-24 개시 Cantor Fitzgerald Overweight
2019-01-24 업그레이드 Leerink Partners Mkt Perform → Outperform
2018-06-26 개시 Stifel Buy
2018-04-02 재확인 Leerink Partners Mkt Perform
2017-05-11 개시 JP Morgan Overweight
2017-03-09 다운그레이드 Leerink Partners Outperform → Mkt Perform
2017-02-09 개시 Credit Suisse Outperform
2016-09-26 개시 Wedbush Outperform
모두보기

Ascendis Pharma A S Adr 주식(ASND)의 최신 뉴스

pulisher
Nov 20, 2024

European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

European Equities Traded in the US as American Depositary Move Higher in Monday Trading - MSN

Nov 20, 2024
pulisher
Nov 04, 2024

Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug - Benzinga

Nov 04, 2024
pulisher
Oct 21, 2024

TD Cowen boosts Ascendis stock target, sees Q3 Skytrofa growth lagging but long-term outlook intact - Investing.com

Oct 21, 2024
pulisher
Oct 14, 2024

Nothing is Better Than Ascendis Pharma A/S ADR (ASND) stock at the moment - SETE News

Oct 14, 2024
pulisher
Oct 14, 2024

Financial Health Report: Ascendis Pharma A/S ADR (ASND)’s Ratios Tell a Tale - The Dwinnex

Oct 14, 2024
pulisher
Oct 09, 2024

Ascendis Pharma A/S ADR’s Banking’s 100-Day Moving Average at 134.03: Will the Stock Break Through? - The InvestChronicle

Oct 09, 2024
pulisher
Oct 09, 2024

Stock Market Recap: Ascendis Pharma A/S ADR (ASND) Concludes at 132.05, a -5.10 Surge/Decline - The Dwinnex

Oct 09, 2024
pulisher
Oct 03, 2024

The Ascendis Pharma A/S ADR (ASND) had a good session last reading, didn’t it? - US Post News

Oct 03, 2024
pulisher
Oct 01, 2024

Stocks Showing Rising Market Leadership: Ascendis Pharma ADR Earns 83 RS Rating - Investor's Business Daily

Oct 01, 2024
pulisher
Sep 30, 2024

Top investors say Ascendis Pharma A/S ADR (ASND) ticks everything they need - SETE News

Sep 30, 2024
pulisher
Sep 30, 2024

Ascendis reports positive 3-year hypoparathyroidism trial data - Investing.com

Sep 30, 2024
pulisher
Sep 25, 2024

Results from Ascendis Pharma A/S ADR (ASND) show risk - US Post News

Sep 25, 2024
pulisher
Sep 24, 2024

Sei Investments Co. Sells 81,615 Shares of Ascendis Pharma A/S (NASDAQ:ASND) - MarketBeat

Sep 24, 2024
pulisher
Sep 23, 2024

Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $191.00 - MarketBeat

Sep 23, 2024
pulisher
Sep 22, 2024

Ascendis Pharma A/S (NASDAQ:ASND) Holdings Lifted by Evolutionary Tree Capital Management LLC - MarketBeat

Sep 22, 2024
pulisher
Sep 19, 2024

European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN

Sep 19, 2024
pulisher
Sep 19, 2024

Investor’s Delight: Ascendis Pharma A/S ADR (ASND) Closes Strong at 148.88, Up 1.56 - The Dwinnex

Sep 19, 2024
pulisher
Sep 19, 2024

Ascendis Pharma launches $300 million public offering - Investing.com

Sep 19, 2024
pulisher
Sep 19, 2024

Ascendis Pharma A/S (NASDAQ:ASND) Shares Acquired by Seven Eight Capital LP - MarketBeat

Sep 19, 2024
pulisher
Sep 18, 2024

Analysts review Ascendis Pharma A/S ADR’s rating - Knox Daily

Sep 18, 2024
pulisher
Sep 18, 2024

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs - Yahoo Finance

Sep 18, 2024
pulisher
Sep 18, 2024

Analyzing Edgewise Therapeutics Inc (EWTX) After Recent Trading Activity - Knox Daily

Sep 18, 2024
pulisher
Sep 18, 2024

Ascendis Pharma A/S ADR (ASND) did well last session? - US Post News

Sep 18, 2024
pulisher
Sep 17, 2024

Ascendis Pharma shares retain Outperform rating, Evercore ISI lifts target citing potential in new patient starts - Investing.com

Sep 17, 2024
pulisher
Sep 17, 2024

Prepare Yourself for Liftoff: Ascendis Pharma A/S ADR (ASND) - SETE News

Sep 17, 2024
pulisher
Sep 17, 2024

Oppenheimer raises Ascendis Pharma shares, maintains Outperform rating - Investing.com India

Sep 17, 2024
pulisher
Sep 16, 2024

Goldman Sachs raises Ascendis Pharma stock price target on study success - Investing.com India

Sep 16, 2024
pulisher
Sep 16, 2024

Jefferies lifts Ascendis Pharma target to $179 on trial data - Investing.com

Sep 16, 2024
pulisher
Sep 16, 2024

Barclays maintains BioMarin at Overweight with $110 target - Investing.com

Sep 16, 2024
pulisher
Sep 16, 2024

Why This Small Biotech Is Hammering BioMarin Today - Investor's Business Daily

Sep 16, 2024
pulisher
Sep 16, 2024

Positive topline data supports Ascendis Pharma stock, analyst highlights potential for weekly injection advantage. - Investing.com India

Sep 16, 2024
pulisher
Sep 16, 2024

Ascendis Pharma reaffirms stock target, buy rating on study success - Investing.com

Sep 16, 2024
pulisher
Sep 16, 2024

Ascendis Pharma reports growth in achondroplasia trial - Investing.com India

Sep 16, 2024
pulisher
Sep 13, 2024

Citi maintains buy on Ascendis with $178 target amid trial data - Investing.com

Sep 13, 2024
pulisher
Sep 13, 2024

Market Insights: Ascendis Pharma A/S ADR (ASND)’s Notable Gain of 0.78, Closing at 113.81 - The Dwinnex

Sep 13, 2024
pulisher
Sep 12, 2024

Ascendis Pharma A/S ADR (ASND)’s highs and lows: A closer look at its stock price fluctuations - US Post News

Sep 12, 2024
pulisher
Sep 10, 2024

Closing Figures Unveiled: Ascendis Pharma A/S ADR (ASND) Drop -1.94, Closes at 116.84 - The Dwinnex

Sep 10, 2024
pulisher
Sep 10, 2024

Citi maintains Ascendis Pharma stock at Buy, positive outlook ahead of pivotal trial data - Investing.com India

Sep 10, 2024
pulisher
Sep 09, 2024

A better buy-in window may exist right now for Ascendis Pharma A/S ADR (ASND) - SETE News

Sep 09, 2024
pulisher
Sep 08, 2024

European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading - MSN

Sep 08, 2024
pulisher
Sep 06, 2024

TD Cowen maintains Buy on Ascendis, keeps $157 target - Investing.com

Sep 06, 2024
pulisher
Sep 06, 2024

Ascendis Pharma A/S ADR (ASND) requires closer examination - US Post News

Sep 06, 2024
pulisher
Sep 05, 2024

Stock Performance Spotlight: Ascendis Pharma A/S ADR (ASND) Ends the Day at 119.50, Down by -11.27 - The Dwinnex

Sep 05, 2024
pulisher
Sep 04, 2024

Jefferies cuts Ascendis share price target amid hGH market pressure - Investing.com

Sep 04, 2024
pulisher
Sep 04, 2024

Goldman Sachs cuts Ascendis Pharma shares target, maintains Buy rating - Investing.com

Sep 04, 2024
pulisher
Sep 04, 2024

Ascendis Pharma stock target cut, retains rating amid Skytrofa sales miss - Investing.com

Sep 04, 2024
pulisher
Sep 04, 2024

Earnings call: Ascendis Pharma reports mixed Q2 2024 results, forecasts growth - Investing.com

Sep 04, 2024
pulisher
Sep 04, 2024

Biotech Makes A Bearish Move On Drug-Pricing Fiasco - Investor's Business Daily

Sep 04, 2024
pulisher
Sep 04, 2024

Taking on analysts’ expectations and winning: Ascendis Pharma A/S ADR (ASND) - SETE News

Sep 04, 2024

Ascendis Pharma A S Adr (ASND) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
자본화:     |  볼륨(24시간):